American Journal of Epidemiology Advance Access originally published online on January 18, 2006
American Journal of Epidemiology 2006 163(6):521-527; doi:10.1093/aje/kwj072
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Contribution |
Risk of Second Primary Malignancies in Women with Papillary Thyroid Cancer
From the Northern California Cancer Center, Fremont, California
Correspondence to Alison Canchola, Northern California Cancer Center, 2201 Walnut Avenue, Suite 300, Fremont, CA 94538 (e-mail: acanchol{at}nccc.org).
Second malignancies in women diagnosed with thyroid cancer are of concern given the young average age at diagnosis and excellent survival. Data from the California Cancer Registry were used to evaluate the risk of second primary cancers among a retrospective population-based cohort of 10,932 women diagnosed with papillary thyroid cancer between 1988 and 1999. Follow-up was calculated from 2 months until the diagnosis of a second primary cancer, death, loss to follow-up, or December 31, 1999, whichever occurred first. Standardized incidence ratios, based on age-specific cancer incidence rates for California women, were calculated. During a total of 50,938 person-years of follow-up (mean: 4.7 years), 279 women developed a second primary cancer. The incidence of invasive breast cancer was not elevated compared with California women overall (standardized incidence ratio (SIR) = 0.9, 95% confidence interval (CI): 0.7, 1.1) or when stratified by age, race/ethnicity, follow-up, or radiation treatment. An excess of in situ breast cancer (SIR = 1.6, 95% CI: 1.0, 2.4), kidney cancer (SIR = 3.9, 95% CI: 2.2, 6.3), and melanoma (SIR = 2.1, 95% CI: 1.3, 3.2) limited to the first 5 years after diagnosis was observed. Women with papillary thyroid cancer are at increased risk of in situ, but not invasive, breast cancer, kidney cancer, and melanoma.
breast neoplasms; kidney neoplasms; melanoma; neoplasms, second primary; thyroid neoplasms
Abbreviations: CI, confidence interval; RR, relative risk; SIR, standardized incidence ratio
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Aaron. P. Brown, J. Chen, Y. J. Hitchcock, A. Szabo, D. C. Shrieve, and Jonathan. D. Tward The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 504 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mayr, B. Fuger, and A. Staudenherz 'Increased incidence of secondary tumours in thyroid cancer patients': a fact or a sophism? Eur. J. Endocrinol., September 1, 2007; 157(3): 369 - 369. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sioka, A. Zouboulidis, A. Fotopoulos, and N. Dimakopoulos RE: "RISK OF SECOND PRIMARY MALIGNANCIES IN WOMEN WITH PAPILLARY THYROID CANCER" Am. J. Epidemiol., February 15, 2007; 165(4): 473 - 473. [Full Text] [PDF]
|
|
|
|
|
|
P. L. Horn-Ross and A. J. Canchola TWO OF THE AUTHORS REPLY Am. J. Epidemiol., February 15, 2007; 165(4): 474 - 474. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hayat, N. Howlader, M. E. Reichman, and B. K. Edwards Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program Oncologist, January 1, 2007; 12(1): 20 - 37. [Abstract] [Full Text] [PDF]
|
|